CRISPR and CAR T-Cells for Cancer: Dr. Bing Wang Explains Company's Innovative Approach and More
In this interview, Dr. Wang talks about his company's unique technology that merges CRISPR and CAR T-Cells For treatment in solid tumor cancers. Also, how the coronavirus pandemic is affecting the biotech community.
Dr. Wang is CEO of Refuge, a company he co-founded following nearly a decade of life science investment banking experience. He most recently served as director of healthcare investment banking at Barclays Capital, where he served as strategic financial advisor and helped raised capital for companies in the healthcare industry. Dr. Wang, a cancer survivor who is passionate about bringing forth “smarter” medicines that will transform cancer care, earned a B.S. in Applied Physics from Columbia University, an MBA from Columbia Business School, and a Ph.D. in Electrical Engineering from Princeton University.
Create your
podcast in
minutes
It is Free